Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

It was reported that exenatide ameliorated renal injury in diabetic rats.

The present study was carried out to evaluate the effect of exenatide on 24-hour urinary albumin, urinary transforming growth factor-β(1) (TGF-β(1)) and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.

Who Took Part

The study group was 31 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

31 type 2 diabetic patients with microalbuminuria were randomly allocated to receive exenatide (group Exe, n = 13) or glimepiride treatment (group Glm, n = 18) for 16 weeks.

Body mass index (BMI), fasting plasma glucose, 2-hour postprandial plasma glucose, glycated hemoglobin A(1c), systolic blood pressure, diastolic blood pressure, 24-hour urinary albumin, urinary TGF-β(1) and type IV collagen concentration were analyzed between the two treatment groups. 20 age- and BMI-matched healthy subjects were chosen as the normal control group (group NC, n = 20).

How the Study Was Run

In design terms this was a randomized study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The timeline in the abstract includes 16 weeks.

What Was Measured

PubMed files the paper under topics including Albuminuria, Biomarkers, Collagen Type IV, Diabetes Mellitus, Type 2, Exenatide, Hypoglycemic Agents and Peptides.

What This Means in Plain Language

The paper is a randomized study of Exenatide in 31 patients over 16 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (Kidney & blood pressure research), a journal based in Switzerland.

More context: the Exenatide compound page, all human trials.